File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility
  • Basic View
  • Metadata View
  • XML View
TitleSingle nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility
 
AuthorsYang, CQ1
Chan, KYK1
Ngan, HYS1
Khoo, US1
Chiu, PM1
Chan, QKY1
Xue, WC1
Cheung, ANY1
 
Issue Date2006
 
PublisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/
 
CitationCarcinogenesis, 2006, v. 27 n. 7, p. 1502-1506 [How to Cite?]
DOI: http://dx.doi.org/10.1093/carcin/bgl014
 
AbstractEpidemiological studies suggested that ovulation was associated with ovarian carcinogenesis. Follicle-stimulating hormone (FSH) played an important role in follicular development and was recently found to affect growth of ovarian epithelial cells. Single nucleotide polymorphisms (SNPs) Thr307Ala and Asn680Ser were two non-synonymous variations in the coding region of the FSH receptor (FSHR) gene. This hitherto first case-control study investigating the association between these two FSHR SNPs and the risk of ovarian cancer involved 202 histopathologically confirmed ovarian cancer patients and 266 age-matched cancer-free control subjects using restriction fragment length polymorphism assay and direct sequencing. Our results demonstrated that the 307Ala and 680Ser carriers were associated with significantly increased risk of developing serous and mucinous types of ovarian cancers (P < 0.0005, OR = 2.60, 95% CI = 1.56-4.34; and P < 0.0005, OR = 2.89, 95% CI = 1.73-4.84, adjusted for age, respectively) but not endometrioid and clear cell types. The two SNPs were found to be in modest linkage disequilibrium, D′ = 0.804 and 0.701, r 2 = 0.581 and 0.406 for the cancer and control groups, respectively. The major haplotype of 307Ala-680Ser was also associated with higher cancer risk (P = 0.033, OR = 1.39, 95% CI = 1.03-1.88), especially for the serous and mucinous carcinomas (P = 0.001, OR = 1.82, 95% CI = 1.27-2.60). Our results suggested that the two FSHR SNPs might affect the susceptibility of women to specific subtypes of ovarian cancer. Different types of ovarian cancer might adopt distinct carcinogenetic pathways. Such understanding may be important in selecting patients for ovulation induction therapy. © 2006 Oxford University Press.
 
ISSN0143-3334
2013 Impact Factor: 5.266
 
DOIhttp://dx.doi.org/10.1093/carcin/bgl014
 
ISI Accession Number IDWOS:000238906200025
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYang, CQ
 
dc.contributor.authorChan, KYK
 
dc.contributor.authorNgan, HYS
 
dc.contributor.authorKhoo, US
 
dc.contributor.authorChiu, PM
 
dc.contributor.authorChan, QKY
 
dc.contributor.authorXue, WC
 
dc.contributor.authorCheung, ANY
 
dc.date.accessioned2010-09-06T09:27:20Z
 
dc.date.available2010-09-06T09:27:20Z
 
dc.date.issued2006
 
dc.description.abstractEpidemiological studies suggested that ovulation was associated with ovarian carcinogenesis. Follicle-stimulating hormone (FSH) played an important role in follicular development and was recently found to affect growth of ovarian epithelial cells. Single nucleotide polymorphisms (SNPs) Thr307Ala and Asn680Ser were two non-synonymous variations in the coding region of the FSH receptor (FSHR) gene. This hitherto first case-control study investigating the association between these two FSHR SNPs and the risk of ovarian cancer involved 202 histopathologically confirmed ovarian cancer patients and 266 age-matched cancer-free control subjects using restriction fragment length polymorphism assay and direct sequencing. Our results demonstrated that the 307Ala and 680Ser carriers were associated with significantly increased risk of developing serous and mucinous types of ovarian cancers (P < 0.0005, OR = 2.60, 95% CI = 1.56-4.34; and P < 0.0005, OR = 2.89, 95% CI = 1.73-4.84, adjusted for age, respectively) but not endometrioid and clear cell types. The two SNPs were found to be in modest linkage disequilibrium, D′ = 0.804 and 0.701, r 2 = 0.581 and 0.406 for the cancer and control groups, respectively. The major haplotype of 307Ala-680Ser was also associated with higher cancer risk (P = 0.033, OR = 1.39, 95% CI = 1.03-1.88), especially for the serous and mucinous carcinomas (P = 0.001, OR = 1.82, 95% CI = 1.27-2.60). Our results suggested that the two FSHR SNPs might affect the susceptibility of women to specific subtypes of ovarian cancer. Different types of ovarian cancer might adopt distinct carcinogenetic pathways. Such understanding may be important in selecting patients for ovulation induction therapy. © 2006 Oxford University Press.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationCarcinogenesis, 2006, v. 27 n. 7, p. 1502-1506 [How to Cite?]
DOI: http://dx.doi.org/10.1093/carcin/bgl014
 
dc.identifier.citeulike739404
 
dc.identifier.doihttp://dx.doi.org/10.1093/carcin/bgl014
 
dc.identifier.epage1506
 
dc.identifier.hkuros119653
 
dc.identifier.isiWOS:000238906200025
 
dc.identifier.issn0143-3334
2013 Impact Factor: 5.266
 
dc.identifier.issue7
 
dc.identifier.openurl
 
dc.identifier.pmid16574671
 
dc.identifier.scopuseid_2-s2.0-33745618981
 
dc.identifier.spage1502
 
dc.identifier.urihttp://hdl.handle.net/10722/87255
 
dc.identifier.volume27
 
dc.languageeng
 
dc.publisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofCarcinogenesis
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCarcinogenesis. Copyright © Oxford University Press.
 
dc.subject.meshBase Sequence
 
dc.subject.meshCase-Control Studies
 
dc.subject.meshFemale
 
dc.subject.meshGenetic Predisposition to Disease
 
dc.subject.meshHumans
 
dc.subject.meshOvarian Neoplasms - genetics
 
dc.subject.meshPolymerase Chain Reaction
 
dc.subject.meshPolymorphism, Restriction Fragment Length
 
dc.subject.meshPolymorphism, Single Nucleotide - genetics
 
dc.subject.meshReceptors, FSH - genetics
 
dc.subject.meshRisk Factors
 
dc.titleSingle nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yang, CQ</contributor.author>
<contributor.author>Chan, KYK</contributor.author>
<contributor.author>Ngan, HYS</contributor.author>
<contributor.author>Khoo, US</contributor.author>
<contributor.author>Chiu, PM</contributor.author>
<contributor.author>Chan, QKY</contributor.author>
<contributor.author>Xue, WC</contributor.author>
<contributor.author>Cheung, ANY</contributor.author>
<date.accessioned>2010-09-06T09:27:20Z</date.accessioned>
<date.available>2010-09-06T09:27:20Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>Carcinogenesis, 2006, v. 27 n. 7, p. 1502-1506</identifier.citation>
<identifier.issn>0143-3334</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/87255</identifier.uri>
<description.abstract>Epidemiological studies suggested that ovulation was associated with ovarian carcinogenesis. Follicle-stimulating hormone (FSH) played an important role in follicular development and was recently found to affect growth of ovarian epithelial cells. Single nucleotide polymorphisms (SNPs) Thr307Ala and Asn680Ser were two non-synonymous variations in the coding region of the FSH receptor (FSHR) gene. This hitherto first case-control study investigating the association between these two FSHR SNPs and the risk of ovarian cancer involved 202 histopathologically confirmed ovarian cancer patients and 266 age-matched cancer-free control subjects using restriction fragment length polymorphism assay and direct sequencing. Our results demonstrated that the 307Ala and 680Ser carriers were associated with significantly increased risk of developing serous and mucinous types of ovarian cancers (P &lt; 0.0005, OR = 2.60, 95% CI = 1.56-4.34; and P &lt; 0.0005, OR = 2.89, 95% CI = 1.73-4.84, adjusted for age, respectively) but not endometrioid and clear cell types. The two SNPs were found to be in modest linkage disequilibrium, D&#8242; = 0.804 and 0.701, r 2 = 0.581 and 0.406 for the cancer and control groups, respectively. The major haplotype of 307Ala-680Ser was also associated with higher cancer risk (P = 0.033, OR = 1.39, 95% CI = 1.03-1.88), especially for the serous and mucinous carcinomas (P = 0.001, OR = 1.82, 95% CI = 1.27-2.60). Our results suggested that the two FSHR SNPs might affect the susceptibility of women to specific subtypes of ovarian cancer. Different types of ovarian cancer might adopt distinct carcinogenetic pathways. Such understanding may be important in selecting patients for ovulation induction therapy. &#169; 2006 Oxford University Press.</description.abstract>
<language>eng</language>
<publisher>Oxford University Press. The Journal&apos;s web site is located at http://carcin.oxfordjournals.org/</publisher>
<relation.ispartof>Carcinogenesis</relation.ispartof>
<rights>Carcinogenesis. Copyright &#169; Oxford University Press.</rights>
<subject.mesh>Base Sequence</subject.mesh>
<subject.mesh>Case-Control Studies</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Genetic Predisposition to Disease</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Ovarian Neoplasms - genetics</subject.mesh>
<subject.mesh>Polymerase Chain Reaction</subject.mesh>
<subject.mesh>Polymorphism, Restriction Fragment Length</subject.mesh>
<subject.mesh>Polymorphism, Single Nucleotide - genetics</subject.mesh>
<subject.mesh>Receptors, FSH - genetics</subject.mesh>
<subject.mesh>Risk Factors</subject.mesh>
<title>Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0143-3334&amp;volume=27&amp;spage=1502&amp;epage=6&amp;date=2006&amp;atitle=Single+nucleotide+polymorphisms+of+follicle-stimulating+hormone+receptor+are+associated+with+ovarian+cancer+susceptibility</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1093/carcin/bgl014</identifier.doi>
<identifier.pmid>16574671</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33745618981</identifier.scopus>
<identifier.hkuros>119653</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33745618981&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>27</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>1502</identifier.spage>
<identifier.epage>1506</identifier.epage>
<identifier.isi>WOS:000238906200025</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>739404</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong